Management of patients with epidermal growth factor receptor mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC) after radiological progression to first-line therapy with gefitinib.

被引：0
|
作者：
Hosomi, Yukio
Tanai, Chiharu
Yoh, Kiyotaka
Goto, Yasushi
Ohashi, Yasuo
Kunitoh, Hideo
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[2] NTT Med Ctr, Div Respirol, Tokyo, Japan
[3] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[4] Natl Canc Ctr, Tokyo, Japan
[5] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Tokyo 112, Japan
[6] Japanese Red Cross Med Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19124
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FIRST-LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR plus ) NON-SMALL CELL LUNG CANCER (NSCLC) IN AN ISRAELI COHORT
    Ben-Arieh, S.
    Urban, D.
    Maimon, N.
    Leibowitz-Amit, R.
    Keizman, D.
    Biran, H.
    Mishaeli, M.
    Onn, A.
    Gottfried, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [2] Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib
    Nie, Xin
    Zhang, Ping
    Cheng, Gang
    Wu, Xiao-Nan
    Li, Lin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (01) : 150 - 155
  • [3] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)
    Vishwanathan, Karthick
    Dunyak, James
    Overend, Philip
    Hartmaier, Ryan
    Markovets, Aleksandra
    Chmielecki, Juliann
    Mugundu, Ganesh
    Barrett, Carl
    Tomkinson, Helen
    Johnson, Martin
    CANCER RESEARCH, 2020, 80 (16)
  • [5] The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden
    Nilsson, Fredrik O. L.
    Gal, Peter
    Houisse, Ivan
    Ivanova, Jasmina I.
    Asanin, Sandra T.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 447 - 457
  • [6] Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
    Lopes, G.
    Segel, J.
    Tan, D. S. W.
    Do, Y.
    Mok, T.
    Finkelstein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
    Ke, E-E
    Wu, Yi-Long
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) : 256 - 264
  • [8] Real-world, first-line Osimertinib treatment in epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y. -H
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Sawyer, W.
    Shenolikar, R.
    Shaw, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 254 - 254
  • [9] Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC
    Nieva, J.
    Griesinger, F.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Sawyer, W.
    Shenolikar, R.
    Shaw, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S616 - S617
  • [10] OBSERVATIONAL STUDY OF TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION POSITIVE (EGFRM plus ) ADVANCED OR RECURRENT NON-SMALL-CELL LUNG CANCER (NSCLC), AFTER RADIOLOGICAL PROGRESSION TO THE FIRST-LINE THERAPY WITH EGFR TYROSINE KINASE INHIBITORS (EGFR-TKI)
    Kunitoh, Hideo
    Tanai, Chiharu
    Hosomi, Yukio
    Yoh, Kiyotaka
    Goto, Yasushi
    Ohashi, Yasuo
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S597 - S598
12345